These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11342329)

  • 1. The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.
    Savoldo B; Heslop HE; Rooney CM
    Leuk Lymphoma; 2000 Nov; 39(5-6):455-64. PubMed ID: 11342329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
    Sun Q; Burton R; Reddy V; Lucas KG
    Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
    Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
    Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
    Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
    Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
    Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.
    Heslop HE; Perez M; Benaim E; Rochester R; Brenner MK; Rooney CM
    J Clin Apher; 1999; 14(3):154-6. PubMed ID: 10540372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.
    Hoffmann T; Russell C; Vindelov L
    APMIS; 2002 Feb; 110(2):148-57. PubMed ID: 12064870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation.
    Uhlin M; Okas M; Gertow J; Uzunel M; Brismar TB; Mattsson J
    Cancer Immunol Immunother; 2010 Mar; 59(3):473-7. PubMed ID: 19908041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
    Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
    Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
    Norville R; Nance D; Cheshire S
    J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
    Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
    Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.